On April 16-18, VCBeat Research hosted the Fifth Future Healthcare VB100 Conference in Wujiang, Suzhou. At the conference, Keya Medical was ranked sixth on the Top 100 Future Medical Companies List as a result of its research and development strength, commercial deployment potential, and recent accomplishments in the medical imaging AI field.

The Future Healthcare VB100 Conference recognizes leading companies that are at the forefront of the global healthcare industry. This year, the conference brought together more than 10,000 industry experts from top medical, academic, and research institutions worldwide.

Keya Medical has adhered to the corporate philosophy of developing diagnosis and treatment solutions that solve real clinical challenges. In January 2020, Keya Medical’s core product, DeepVessel FFR, became the first AI-empowered Class III medical device approved by the NMPA for commercialization in China. The software uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computed tomography angiogram (CTA) scans, reducing unnecessary invasive testing. Keya Medical is also the second company in the world to obtain necessary approvals to commercialize AI-empowered medical devices in China, the United States, and the European Union.

Keya Medical will continue to develop deep learning-based medical devices for disease diagnosis and treatment, with a goal to revolutionize the medical device industry in China.

About Keya Medical
Keya Medical Technology Co. Ltd. is a medical technology company dedicated to the development and commercialization of deep learning-based medical devices for disease diagnosis and treatment with a goal to revolutionize the medical device industry. Since 2016, Keya Medical has developed solutions for specialties, including cardiology, radiology, neurology, pathology, and surgery. Today, the company collaborates with 728 hospitals to improve care delivery on a global scale. To learn more about Keya Medical, follow us on LinkedIn, Facebook, and Twitter.